共 50 条
More than a messenger: Alternative splicing as a therapeutic target
被引:29
作者:
Black, A. J.
[1
]
Gomorra, J. R.
[1
]
Giudicea, J.
[1
,2
]
机构:
[1] Univ N Carolina, Sch Med, Dept Cell Biol & Physiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Sch Med, McAllister Heart Inst, Chapel Hill, NC 27515 USA
来源:
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
|
2019年
/
1862卷
/
11-12期
基金:
美国国家卫生研究院;
关键词:
Alternative splicing;
Antisense oligonucleotides;
RNA therapeutics;
Spliceosome;
RNA binding proteins;
RNA binding drugs;
SPINAL MUSCULAR-ATROPHY;
SURVIVAL-MOTOR-NEURON;
PROTEIN-KINASES;
IN-VITRO;
ANTISENSE OLIGONUCLEOTIDE;
SINGLE NUCLEOTIDE;
DNA-METHYLATION;
CRITICAL EXON;
OPEN-LABEL;
2ND STEP;
D O I:
10.1016/j.bbagrm.2019.06.006
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Alternative splicing of pre-mRNA is an essential post- and co-transcriptional mechanism of gene expression regulation that produces multiple mature mRNA transcripts from a single gene. Genetic mutations that affect splicing underlie numerous devastating diseases. The complexity of splicing regulation allows for multiple therapeutic approaches to correct disease-associated mis-splicing events. In this review, we first highlight recent findings from therapeutic strategies that have used splice switching antisense oligonucleotides and small molecules that bind directly to RNA. Second, we summarize different genetic and chemical approaches to target components of the spliceosome to correct splicing defects in pathological conditions. Finally, we present an overview of compounds that target kinases and accessory pathways that intersect with the splicing machinery. Advancements in the understanding of disease-specific defects caused by mis-regulation of alternative splicing will certainly increase the development of therapeutic options for the clinic. This article is part of a Special Issue entitled: RNA structure and splicing regulation edited by Francisco Baralle, Ravindra Singh and Stefan Stamm.
引用
收藏
页数:13
相关论文